Avidity Biosciences Return on Equity

Avidity Biosciences (RNA) currently reports a ROE of -250.1%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Avidity Biosciences's ROE history and peer comparisons.

Avidity Biosciences's ROE of -250.1% is lower than the Healthcare sector average of 29.33%. That is roughly 952.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Avidity Biosciences's current -250.1% should be judged against Healthcare norms (sector average: 29.33%) and against RNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -250.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Avidity Biosciences, and consider following RNA for alerts when major investors trade the stock.

Avidity Biosciences is classified in the Healthcare sector. On ROE, it currently shows -250.1% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RNA with unrelated industries.